Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817111 · ClinicalTrials.gov registry record · Phase 2
NAD+ Precursor Supplementation in Friedreich's Ataxia
A Phase 2 study, sponsored by Metro International Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT04817111 is a Phase 2 study that has completed, run by Metro International Biotech. The registered enrollment target is 7 participants.
The verdict
NCT04817111, a Phase 2 study, has completed, sponsored by Metro International Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is to test the effects of MIB-626 on cardiac and skeletal muscle bioenergetics.
Interventions
- DRUG MIB-626
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04817111
The ClinicalTrials.gov registry entry for NCT04817111 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Metro International Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MIB-626 is the first listed.
NCT04817111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04817111 about?
NCT04817111 is a clinical study titled "NAD+ Precursor Supplementation in Friedreich's Ataxia". The primary objective is to test the safety and tolerability of short-term therapy with a nicotinamide adenine dinucleotide (NAD+) precursor (MIB-626) in adults with Friedreich's Ataxia (FA) without overt heart failure and with a left ventricular ejection fraction ≥ 40%. A key secondary objective is...
What is the current status of trial NCT04817111?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2021-05-17. Estimated completion is 2022-05-19.
What interventions are being tested in trial NCT04817111?
The interventions under investigation include: MIB-626 (DRUG).
Who is sponsoring clinical trial NCT04817111?
This trial is sponsored by Metro International Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.